Prognostic factors in 382 patients treated with 177-Lu-DOTATATE: Data from the SEPTRALU registry

#3436

Introduction: The aim was to describe prognostic variables in patients treated with 177Lu-DOTATATE (PRRT).

Aim(s): To describe prognostic variables in patients treated with 177Lu-DOTATATE (PRRT).

Materials and methods: The data come from the SEPTRALU national, multicenter (23 hospitals) and ambispective (June 2013-November 2021) study. Patients with somatostatin receptor–positive tumours were included. 97 patients with no available follow-up were excluded. The coordinating committee selected 7 potential prognostic variables based on previous evidence and considering sample size: ECOG (0-1 vs >1), Ki67% (continuous variable), tumor site (midgut vs others), extrahepatic/extranodal metastases (present vs absent), Krenning (>2 vs ≤2), previous line of systemic treatment including somatostatin analogues (>1 vs ≤1), and days from diagnosis of advanced tumor to PRRT (continuous variable). Cox proportional risk regression was used to analyse prognostic variables.

Conference:

Presenting Author:

Authors: Pubul V, Belló P, Hernando J, Rodeño E, Gajate P,

Keywords: somatostatin receptor-positive tumor, PRRT, prognostic variables,